{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T05:23:14Z","timestamp":1779081794128,"version":"3.51.4"},"reference-count":61,"publisher":"Walter de Gruyter GmbH","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Background<\/jats:bold>\n                    : The term pseudomyxoma peritonei (PMP) was first described in 1884 and there has been much debate since then over the term. A recent consensus of world experts agreed that PMP should be thought of as a clinical entity characterised by the presence of mucinous ascites, omental cake, peritoneal implants and possibly ovarian involvement. It generally originates from mucinous appendiceal tumours.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Content<\/jats:bold>\n                    : This review details the clinical presentation of this unusual condition, presents the new classification system and how this relates to outcome. The pathophysiology of this disease is also explored with a special reference to the relationship of the disease to tumour markers.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Summary<\/jats:bold>\n                    : A classification system has been agreed upon by the leading experts in PMP which is now divided into low and high grade mucinous carcinomatosis peritonei. This distinction correlates with clinical outcome as does the presence of raised tumour markers preoperatively.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Outlook<\/jats:bold>\n                    : Research needs to be focused on understanding the factors associated with poor prognosis through well designed multi-centred prospective studies. This will allow us to identify patients with bad tumour biology so that targeted treatment based on likely prognosis may then become a reality.\n                  <\/jats:p>","DOI":"10.1515\/pp-2016-0008","type":"journal-article","created":{"date-parts":[[2016,4,13]],"date-time":"2016-04-13T15:15:08Z","timestamp":1460560508000},"page":"3-13","source":"Crossref","is-referenced-by-count":20,"title":["Pathophysiology and classification of pseudomyxoma peritonei"],"prefix":"10.1515","volume":"1","author":[{"given":"Mark","family":"Bignell","sequence":"first","affiliation":[{"name":"Peritoneal Malignancy Institute, Basingstoke, United Kingdom of Great Britain and Northern Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norman J.","family":"Carr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faheez","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2016,4,12]]},"reference":[{"key":"2025120909190354781_j_pp-2016-0008_ref_001_w2aab3b7c30b1b6b1ab2ab1Aa","doi-asserted-by":"crossref","unstructured":"1. Werth R. Klinische and anastomische untersuchungen zur lehre von der bauchgeswullsten und der laparotomy. Arch Gynecol Obstet 1884;84:100\u201318.","DOI":"10.1007\/BF01837425"},{"key":"2025120909190354781_j_pp-2016-0008_ref_002_w2aab3b7c30b1b6b1ab2ab2Aa","unstructured":"2. Frankel E. Uher das sogenaute pseudomyxoma peritonei. Med Wochenschr 1901;48:965\u201370."},{"key":"2025120909190354781_j_pp-2016-0008_ref_003_w2aab3b7c30b1b6b1ab2ab3Aa","doi-asserted-by":"crossref","unstructured":"3. Carr NJ, Cecil TD, Mohamed F, Sobin LH, Sugarbaker PH, Gonz\u00e1lez-Moreno S, et al. A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia. Am J Surg Pathol 2016;40:14\u201326.","DOI":"10.1097\/PAS.0000000000000535"},{"key":"2025120909190354781_j_pp-2016-0008_ref_004_w2aab3b7c30b1b6b1ab2ab4Aa","unstructured":"4. Carr NJ, Finch J, Ilesley IC, Chandrakumaran K, Mohamed F, Mirnezami A, et al. Pathology and prognosis in pseudomyxoma peritonei: a review of 274 cases. J Clin Pathol 2004;21:134\u201350."},{"key":"2025120909190354781_j_pp-2016-0008_ref_005_w2aab3b7c30b1b6b1ab2ab5Aa","unstructured":"5. Carr NJ, Sobin LH. Unusual tumors of the appendix and pseudomyxoma peritonei. Semin Diagn Pathol 1996;13:314\u201325."},{"key":"2025120909190354781_j_pp-2016-0008_ref_006_w2aab3b7c30b1b6b1ab2ab6Aa","doi-asserted-by":"crossref","unstructured":"6. Connor SJ, Hanna GB, Frizelle FA. Appendiceal tumours: retrospective clinicopathologic analysis of appendiceal tumours from 7,970 appendicetomies. Dis Colon Rectum 1998;41:75.","DOI":"10.1007\/BF02236899"},{"key":"2025120909190354781_j_pp-2016-0008_ref_007_w2aab3b7c30b1b6b1ab2ab7Aa","doi-asserted-by":"crossref","unstructured":"7. Smeenk RM, van Velthuysen ML, Verwaal VJ, Zoetmulder FA. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol 2008;34:196\u2013201.","DOI":"10.1016\/j.ejso.2007.04.002"},{"key":"2025120909190354781_j_pp-2016-0008_ref_008_w2aab3b7c30b1b6b1ab2ab8Aa","doi-asserted-by":"crossref","unstructured":"8. Khan MN, Moran BJ. Four percent of patients undergoing colorectal cancer surgery may have synchronous appendiceal neoplasia. Dis Colon Rectum 2007;50:1856\u20139.","DOI":"10.1007\/s10350-007-9033-2"},{"key":"2025120909190354781_j_pp-2016-0008_ref_009_w2aab3b7c30b1b6b1ab2ab9Aa","doi-asserted-by":"crossref","unstructured":"9. Moran B, Cecil T, Chandrakumaran K, Arnold S, Mohamed F, Venkatasubramaniam A. The results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1200 patients with peritoneal malignancy. Colorectal Dis 2015;17:772\u20138.","DOI":"10.1111\/codi.12975"},{"key":"2025120909190354781_j_pp-2016-0008_ref_010_w2aab3b7c30b1b6b1ab2ac10Aa","doi-asserted-by":"crossref","unstructured":"10. Dayal S, Taflampas P, Riss S, Chandrakumaran K, Cecil TD, Mohamed F, et al. Complete cytoreduction for pseudomyxoma peritonei is optimal but maximal tumor debulking may be beneficial in patients in whom complete tumor removal cannot be achieved. Dis Colon Rectum 2013;56:1366\u201372.","DOI":"10.1097\/DCR.0b013e3182a62b0d"},{"key":"2025120909190354781_j_pp-2016-0008_ref_011_w2aab3b7c30b1b6b1ab2ac11Aa","doi-asserted-by":"crossref","unstructured":"11. Esquivel J, Sugabaker PH. Clinical presentation of the pseudomyxoma peritonei syndrome. Br J Surg 2000;87:1414\u201318.","DOI":"10.1046\/j.1365-2168.2000.01553.x"},{"key":"2025120909190354781_j_pp-2016-0008_ref_012_w2aab3b7c30b1b6b1ab2ac12Aa","unstructured":"12. Glaysher M, Gordon-Dixon A, Chandrakumaran K, Cecil TD, Moran BJ. Pseudomyxoma peritonei of appendiceal origin: mode of presentation in the modern era [abstract]. Colorectal Dis 2014;16(suppl 2):53."},{"key":"2025120909190354781_j_pp-2016-0008_ref_013_w2aab3b7c30b1b6b1ab2ac13Aa","doi-asserted-by":"crossref","unstructured":"13. Esquivel J, Sugarbaker PH. Pseudomyxoma peritonei in a hernia sac: analysis of 20 patients in whom mucoid fluid was found during a hernia repair. Eur J Surg Oncol 2001;27:54\u20138.","DOI":"10.1053\/ejso.2000.1031"},{"key":"2025120909190354781_j_pp-2016-0008_ref_014_w2aab3b7c30b1b6b1ab2ac14Aa","doi-asserted-by":"crossref","unstructured":"14. Murphy EM, Farquharson SM, Moran BJ. Management of an unexpected appendiceal neoplasm. Br J Surg 2006;93:783\u201392.","DOI":"10.1002\/bjs.5385"},{"key":"2025120909190354781_j_pp-2016-0008_ref_015_w2aab3b7c30b1b6b1ab2ac15Aa","doi-asserted-by":"crossref","unstructured":"15. O\u2019Connell JT, Hacker CM, Barsky SH. MUC2 is a molecular marker for pseudomyxoma. Mod Pathol 2002;15:958\u201372.","DOI":"10.1097\/01.MP.0000026617.52466.9F"},{"key":"2025120909190354781_j_pp-2016-0008_ref_016_w2aab3b7c30b1b6b1ab2ac16Aa","doi-asserted-by":"crossref","unstructured":"16. Wang J, El-Bahrawy MA. Expression profile of mucins in ovarian mucinous tumours: distinguishing primary ovarian from metastatic tumours. Int J Gynaecol Pathol 2014;33:166\u201375.","DOI":"10.1097\/PGP.0b013e318288b384"},{"key":"2025120909190354781_j_pp-2016-0008_ref_017_w2aab3b7c30b1b6b1ab2ac17Aa","doi-asserted-by":"crossref","unstructured":"17. Chu PG, Chung L, Weiss LM, Lau SK. Determining the site of origin of mucinous adenocarcinoma: an immunohistochemical study of 175 cases. Am J Surg Pathol 2011;35:1830\u20136.","DOI":"10.1097\/PAS.0b013e3182299c25"},{"key":"2025120909190354781_j_pp-2016-0008_ref_018_w2aab3b7c30b1b6b1ab2ac18Aa","doi-asserted-by":"crossref","unstructured":"18. Nonaka D, Kusamura S, Baratti D, Casali P, Younan R, Deraco M. CDX-2 expression in pseudomyxoma peritonei: a clinicopathological study of 42 cases Histopathology 2006;49:381\u20137.","DOI":"10.1111\/j.1365-2559.2006.02512.x"},{"key":"2025120909190354781_j_pp-2016-0008_ref_019_w2aab3b7c30b1b6b1ab2ac19Aa","doi-asserted-by":"crossref","unstructured":"19. Yajima N, Wada R, Yamagishi S, Mizukami H, Itabashi C, Yagihashi S. Immunohistochemical expressions of cytokeratins, mucin core proteins, p53, and neuroendocrine cell markers in epithelial neoplasm of appendix. Hum Pathol 2005;36:1217\u201325.","DOI":"10.1016\/j.humpath.2005.08.022"},{"key":"2025120909190354781_j_pp-2016-0008_ref_020_w2aab3b7c30b1b6b1ab2ac20Aa","doi-asserted-by":"crossref","unstructured":"20. Baratti D, Kusamura S, Nonaka D, Langer M, Andreola S, Favaro M, et al. Pseudomyxoma peritonei: clinical, pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 2008;15:526\u201334.","DOI":"10.1245\/s10434-007-9691-2"},{"key":"2025120909190354781_j_pp-2016-0008_ref_021_w2aab3b7c30b1b6b1ab2ac21Aa","doi-asserted-by":"crossref","unstructured":"21. Chu P, Wu E, Weiss LM. Cytokeratin 7 and Cytokeratin 20 expression in epithelial neoplasms: a survery of 435 cases. Mod Pathol 2000;13:962\u201372.","DOI":"10.1038\/modpathol.3880175"},{"key":"2025120909190354781_j_pp-2016-0008_ref_022_w2aab3b7c30b1b6b1ab2ac22Aa","doi-asserted-by":"crossref","unstructured":"22. Baratti D, Kusamura S, Nonaka D, Cabras AD, Laterza B, Deraco M. Pseudomyxoma peritonei: biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg 2009;249(2):243\u20139.","DOI":"10.1097\/SLA.0b013e31818eec64"},{"key":"2025120909190354781_j_pp-2016-0008_ref_023_w2aab3b7c30b1b6b1ab2ac23Aa","doi-asserted-by":"crossref","unstructured":"23. Bibi R, Pranesh N, Saunders MP, Wilson MS, O\u2019Dwyer ST, Stern PL, et al. A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritonei. Br J Cancer 2006;95:1258\u201364.","DOI":"10.1038\/sj.bjc.6603398"},{"key":"2025120909190354781_j_pp-2016-0008_ref_024_w2aab3b7c30b1b6b1ab2ac24Aa","doi-asserted-by":"crossref","unstructured":"24. Sugarbaker PH. Pseudomyxoma peritonei. A cancer whose biology is characterised by a redistribution phenomenon. Ann Surg 1994;219:109\u201311.","DOI":"10.1097\/00000658-199402000-00001"},{"key":"2025120909190354781_j_pp-2016-0008_ref_025_w2aab3b7c30b1b6b1ab2ac25Aa","doi-asserted-by":"crossref","unstructured":"25. Vogelstein B, Fearon E, Hamilton S, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal tumour development. N Eng J Med 1998;319:525\u201332.","DOI":"10.1056\/NEJM198809013190901"},{"key":"2025120909190354781_j_pp-2016-0008_ref_026_w2aab3b7c30b1b6b1ab2ac26Aa","doi-asserted-by":"crossref","unstructured":"26. Bell SM, Scott N, Cross D, Sagar P, Lewis FA, Blair GE, et al. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology 1993;104:57\u201364.","DOI":"10.1016\/0016-5085(93)90835-Z"},{"key":"2025120909190354781_j_pp-2016-0008_ref_027_w2aab3b7c30b1b6b1ab2ac27Aa","doi-asserted-by":"crossref","unstructured":"27. Noguchi R, Yano H, Gohda Y, Suda R, Igari T, Ohta Y, et al. Molecular profiles of high-grade and low-grade pseudomyxoma peritonei. Cancer Med 2015;4:1809\u20131816.","DOI":"10.1002\/cam4.542"},{"key":"2025120909190354781_j_pp-2016-0008_ref_028_w2aab3b7c30b1b6b1ab2ac28Aa","doi-asserted-by":"crossref","unstructured":"28. Shetty S, Thomas P, Ramanan B, Sharma P, Govindarajan V, Loggie B. Kras mutations and p53 overexpression in pseudomyxoma peritonei: association with phenotype and prognosis. J Surg Res 2013;180:97\u2013103.","DOI":"10.1016\/j.jss.2012.10.053"},{"key":"2025120909190354781_j_pp-2016-0008_ref_029_w2aab3b7c30b1b6b1ab2ac29Aa","doi-asserted-by":"crossref","unstructured":"29. Nishikawa G, Sekine S, Oqawa R, Matsubara A, Mori T, Taniguchi H, et al. Frequent GNAS mutations in low-grade appendiceal mucinous neoplasms. Br J Cancer 2013;108:951\u20138.","DOI":"10.1038\/bjc.2013.47"},{"key":"2025120909190354781_j_pp-2016-0008_ref_030_w2aab3b7c30b1b6b1ab2ac30Aa","doi-asserted-by":"crossref","unstructured":"30. Sio T, Mansfield A, Grotz T, Graham RP, Molina JR, Que FG, et al. Concurrent MCL1 and JUN amplification in pseudomyxoma peritonei: a comprehensive genetic profiling and survival analysis. J Hum Genet 2014;59:124\u20138.","DOI":"10.1038\/jhg.2013.132"},{"key":"2025120909190354781_j_pp-2016-0008_ref_031_w2aab3b7c30b1b6b1ab2ac31Aa","doi-asserted-by":"crossref","unstructured":"31. Liu X, Mody K, de Abreu F, Pipas JM, Peterson JD, Gallagher TL, et al. Molecular profiling of appendiceal epithelial tumours using massively parallel sequencing to identify somatic mutations. Clin Chem 2014;60:1004\u201311.","DOI":"10.1373\/clinchem.2014.225565"},{"key":"2025120909190354781_j_pp-2016-0008_ref_032_w2aab3b7c30b1b6b1ab2ac32Aa","doi-asserted-by":"crossref","unstructured":"32. Alakus H, Babicky M, Ghosh P, Yost S, Jepsen K, Dai Y, et al. Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin. Genome Med 2014;6:43\u201354.","DOI":"10.1186\/gm559"},{"key":"2025120909190354781_j_pp-2016-0008_ref_033_w2aab3b7c30b1b6b1ab2ac33Aa","doi-asserted-by":"crossref","unstructured":"33. Numella P, Saarinen L, Theil A, J\u00e4rvinen P, Lehtonen R, Lepist\u00f6 A, et al. Genomic profile of pseudomyxoma peritonei analysed using next-generation sequencing and immunohistochemistry. Int J Cancer 2015;136:E282\u20139.","DOI":"10.1002\/ijc.29245"},{"key":"2025120909190354781_j_pp-2016-0008_ref_034_w2aab3b7c30b1b6b1ab2ac34Aa","doi-asserted-by":"crossref","unstructured":"34. Nash GM, Gimbel M, Cohen AM, Zeng ZS, Ndubisi MI, Nathanson DR, et al. KRAS mutation and microsatellite instability: two genetic markers of early tumour development that influences the prognosis of colorectal cancer. Ann Surg Oncol 2010;17:416\u201324.","DOI":"10.1245\/s10434-009-0713-0"},{"key":"2025120909190354781_j_pp-2016-0008_ref_035_w2aab3b7c30b1b6b1ab2ac35Aa","doi-asserted-by":"crossref","unstructured":"35. Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Lacopetta BJ, et al. Kirsten ras mutations in patients with colorectal cancer: the \u2018RASCAL II\u2019 study. Br J Cancer 2001;85:692\u20136.","DOI":"10.1054\/bjoc.2001.1964"},{"key":"2025120909190354781_j_pp-2016-0008_ref_036_w2aab3b7c30b1b6b1ab2ac36Aa","unstructured":"36. Ahnen DJ, Feigl P, Quan G, Fenoglio-Preiser C, Lovato LC, Bunn PA Jr, et al. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res 1998;58:1149\u201358."},{"key":"2025120909190354781_j_pp-2016-0008_ref_037_w2aab3b7c30b1b6b1ab2ac37Aa","doi-asserted-by":"crossref","unstructured":"37. Bokemyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011;22:1535\u201346.","DOI":"10.1093\/annonc\/mdq632"},{"key":"2025120909190354781_j_pp-2016-0008_ref_038_w2aab3b7c30b1b6b1ab2ac38Aa","doi-asserted-by":"crossref","unstructured":"38. Van Cutsem E, K\u00f6hne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Eng J Med 2009;360:1408\u201317.","DOI":"10.1056\/NEJMoa0805019"},{"key":"2025120909190354781_j_pp-2016-0008_ref_039_w2aab3b7c30b1b6b1ab2ac39Aa","doi-asserted-by":"crossref","unstructured":"39. Van Cutsem E, K\u00f6hne CH, L\u00e1ng I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of survival according to tumour KRAS and BRAF mutation status. J Clin Oncol 2011;29:2011\u20132019.","DOI":"10.1200\/JCO.2010.33.5091"},{"key":"2025120909190354781_j_pp-2016-0008_ref_040_w2aab3b7c30b1b6b1ab2ac40Aa","doi-asserted-by":"crossref","unstructured":"40. Furukawa T, Kuboki Y, Tanji E, Yoshida S, Hatori T, Yamamoto M, et al. Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci Rep 2014;1:161.","DOI":"10.1038\/srep00161"},{"key":"2025120909190354781_j_pp-2016-0008_ref_041_w2aab3b7c30b1b6b1ab2ac41Aa","unstructured":"41. Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harbor Perspect Biol 2010;2:a001008."},{"key":"2025120909190354781_j_pp-2016-0008_ref_042_w2aab3b7c30b1b6b1ab2ac42Aa","doi-asserted-by":"crossref","unstructured":"42. Idziaszczyk S, Wilson CH, Smith CG, Adams DJ, Cheadle JP. Analysis of the frequency of GNAS codon 201 mutations in advanced colorectal cancer. Cancer Genet Cytogenet 2010;202:67\u20139.","DOI":"10.1016\/j.cancergencyto.2010.04.023"},{"key":"2025120909190354781_j_pp-2016-0008_ref_043_w2aab3b7c30b1b6b1ab2ac43Aa","doi-asserted-by":"crossref","unstructured":"43. Fecteau RE, Lutterbaugh J, Markowitz SD, Wilis J, Guda K. GNAS mutations identify a set of right-sided, RAS mutant, villous colon cancers. PloS One 2014;9:e87966.","DOI":"10.1371\/journal.pone.0087966"},{"key":"2025120909190354781_j_pp-2016-0008_ref_044_w2aab3b7c30b1b6b1ab2ac44Aa","doi-asserted-by":"crossref","unstructured":"44. Carr NJ, McCarthy WF, Sobin LH. Epithelial noncarcinoid tunors and tumor-like lesions of the appendix. A clinicopathologic study of 184 patients with a multivariate analysis of prognostic factors. Cancer 1995;75:757\u201368.","DOI":"10.1002\/1097-0142(19950201)75:3<757::AID-CNCR2820750303>3.0.CO;2-F"},{"key":"2025120909190354781_j_pp-2016-0008_ref_045_w2aab3b7c30b1b6b1ab2ac45Aa","unstructured":"45. Carr N, Sobin L. Tumors of the appendix. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumours of the digestive system. World Health Organisation classification of tumours, Vol 3. 4th. Lyon, France: IARC Press, 2010:122\u20135."},{"key":"2025120909190354781_j_pp-2016-0008_ref_046_w2aab3b7c30b1b6b1ab2ac46Aa","doi-asserted-by":"crossref","unstructured":"46. Misdraji J. Mucinous epithelial neoplasms of the appendix and pseudomyxoma peritonei. Modern Pathol 2015;28:S67\u2013S79.","DOI":"10.1038\/modpathol.2014.129"},{"key":"2025120909190354781_j_pp-2016-0008_ref_047_w2aab3b7c30b1b6b1ab2ac47Aa","doi-asserted-by":"crossref","unstructured":"47. Pai RK, Beck AH, Norton JA, Longacre TA. Appendiceal mucinous neoplasms: clinicpathologic study of 116 cases with analysis of factors predicting recurrence. Am J Surg Pathol 2009;33:1425\u201339.","DOI":"10.1097\/PAS.0b013e3181af6067"},{"key":"2025120909190354781_j_pp-2016-0008_ref_048_w2aab3b7c30b1b6b1ab2ac48Aa","doi-asserted-by":"crossref","unstructured":"48. MacDonald JR, O\u2019Dwyer ST, Rout S, Chakrabarty B, Sikand K, Fulford PE, et al. Classification of and cytoreductive surgery for low-grade appendiceal mucinous neoplasms. Br J Surg 2012;99:987\u201392.","DOI":"10.1002\/bjs.8739"},{"key":"2025120909190354781_j_pp-2016-0008_ref_049_w2aab3b7c30b1b6b1ab2ac49Aa","doi-asserted-by":"crossref","unstructured":"49. Ronnett BM, Zahn CM, Kurman RJ, Kass ME, Sugarbaker PH, Shmookler BM. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to \u201cpseudomyxoma peritonei\u201d. Am J Surg Pathol 1995;19:1390\u2013408.","DOI":"10.1097\/00000478-199512000-00006"},{"key":"2025120909190354781_j_pp-2016-0008_ref_050_w2aab3b7c30b1b6b1ab2ac50Aa","doi-asserted-by":"crossref","unstructured":"50. Ronnett BM, Yan H, Kurman RJ, Shmookler BM, Sugarbaker PH. Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer 2001;92:85\u201391.","DOI":"10.1002\/1097-0142(20010701)92:1<85::AID-CNCR1295>3.0.CO;2-R"},{"key":"2025120909190354781_j_pp-2016-0008_ref_051_w2aab3b7c30b1b6b1ab2ac51Aa","doi-asserted-by":"crossref","unstructured":"51. Bradley RF, Stewart JH, Russell GB, Ea L, Geisinder KR. Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol 2006;30:551\u20139.","DOI":"10.1097\/01.pas.0000202039.74837.7d"},{"key":"2025120909190354781_j_pp-2016-0008_ref_052_w2aab3b7c30b1b6b1ab2ac52Aa","doi-asserted-by":"crossref","unstructured":"52. Shetty S, Natarajan B, Thomas P, Govindarajan V, Sharma P, Loggie B. Proposed classification of pseudomyxoma peritonei: influence of signet ring cells on survival. Am Surg 2013;79:1171\u20136.","DOI":"10.1177\/000313481307901120"},{"key":"2025120909190354781_j_pp-2016-0008_ref_053_w2aab3b7c30b1b6b1ab2ac53Aa","doi-asserted-by":"crossref","unstructured":"53. Kusamura S, Baratti D, Younan R, Deraco M. The Delphi approach to attain consensus in methodology of local regional therapy for peritoneal surface malignancy. J Surg Oncol 2008;98:217\u201319.","DOI":"10.1002\/jso.21059"},{"key":"2025120909190354781_j_pp-2016-0008_ref_054_w2aab3b7c30b1b6b1ab2ac54Aa","doi-asserted-by":"crossref","unstructured":"54. Jones J, Hunter D. Consensus methods for medical and health services research. Br Med J 1995;311:376\u201380.","DOI":"10.1136\/bmj.311.7001.376"},{"key":"2025120909190354781_j_pp-2016-0008_ref_055_w2aab3b7c30b1b6b1ab2ac55Aa","doi-asserted-by":"crossref","unstructured":"55. Davison JM, Choudry HA, Pingpank JF, Pingpank JF, Ahrendt SA, Holtzman MP, et al. Clinicopathologic and molecular analysis of disseminated appendiceal mucinous neoplasms: identification of factors predicting survival and proposed criteria for a three-tiered assessment of tumour grade. Mod Pathol 2014;27:1521\u201339.","DOI":"10.1038\/modpathol.2014.37"},{"key":"2025120909190354781_j_pp-2016-0008_ref_056_w2aab3b7c30b1b6b1ab2ac56Aa","doi-asserted-by":"crossref","unstructured":"56. Mohamed F, Gething S, Haiba M, Brun EA, Sugarbaker PH. Clinically aggressive pseudomyxoma peritonei: a variant of a histologically indolent process. J Surg Oncol 2004;86:10\u201316.","DOI":"10.1002\/jso.20038"},{"key":"2025120909190354781_j_pp-2016-0008_ref_057_w2aab3b7c30b1b6b1ab2ac57Aa","doi-asserted-by":"crossref","unstructured":"57. Di Fabio F, Aston W, Mohamed F, Chandrakumaran K, Cecil T, Moran B. Elevated tumour markers are normalized in most patients with pseudomyxoma peritonei 7 days after complete tumour removal. Colorectal Dis 2015;17:698\u2013703.","DOI":"10.1111\/codi.12924"},{"key":"2025120909190354781_j_pp-2016-0008_ref_058_w2aab3b7c30b1b6b1ab2ac58Aa","doi-asserted-by":"crossref","unstructured":"58. Van Ruth S, Hart AA, Bonfrer J, Verwaal VJ, Zoetmulder FA. Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2002;9:961\u20137.","DOI":"10.1007\/BF02574513"},{"key":"2025120909190354781_j_pp-2016-0008_ref_059_w2aab3b7c30b1b6b1ab2ac59Aa","doi-asserted-by":"crossref","unstructured":"59. Wagner P, Austin F, Sathaiah M, Magge D, Maduekwe U, Ramalingam L, et al. Significance of serum tumour marker levels in peritoneal carcinomatosis of appendiceal origin. Ann Surg Oncol 2013;20:506\u201314.","DOI":"10.1245\/s10434-012-2627-5"},{"key":"2025120909190354781_j_pp-2016-0008_ref_060_w2aab3b7c30b1b6b1ab2ac60Aa","doi-asserted-by":"crossref","unstructured":"60. Taflampas P, Dayal S, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ. Pre-operative tumour marker status predicts recurrence and survival after complete cytoreduction and hyperthermic intraperitoneal chempotherapy for appendiceal pseudomyxoma peritonei: analysis of 519 patients. Eur J Surg Oncol 2014;40:515\u201320.","DOI":"10.1016\/j.ejso.2013.12.021"},{"key":"2025120909190354781_j_pp-2016-0008_ref_061_w2aab3b7c30b1b6b1ab2ac61Aa","doi-asserted-by":"crossref","unstructured":"61. Alexander-Sefre F, Chandrakumaran K, Banerjee S, Sexton R, Thomas JM, Moran B. Elevated tumour markers prior to complete tumour removal in patients with pseudomyxoma peritonei predict early recurrence. Colorectal Dis 2005;7:382\u20136.","DOI":"10.1111\/j.1463-1318.2005.00773.x"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/pp\/1\/1\/article-p3.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2016-0008\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2016-0008\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T09:50:23Z","timestamp":1765273823000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2016-0008\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,1]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,4,12]]},"published-print":{"date-parts":[[2016,3,1]]}},"alternative-id":["10.1515\/pp-2016-0008"],"URL":"https:\/\/doi.org\/10.1515\/pp-2016-0008","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"value":"2364-768X","type":"electronic"},{"value":"2364-7671","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3,1]]}}}